AstraZeneca PLC ADR

AstraZeneca is a Swedish-based pharmaceutical giant dedicated to discovering and developing innovative treatments for conditions like cancer and respiratory diseases. The company gained popularity during the novel COVID-19 pandemic with the development of viral vector vaccines to treat the virus. The company’s most popular product is Tagrisso—a medication used to treat lung carcinomas.

$69.57
(as of Apr 25, 4:00 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Ticker Information for AstraZeneca PLC ADR

Stock Price
$69.57
Ticker Symbol
AZN
Exchange
NASDAQ

Industry Information for AstraZeneca PLC ADR

Sector
Healthcare
Industry
Drug Manufacturers - General

Company Description for AstraZeneca PLC ADR

Country
USA
Full Time Employees
94,300

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Crestor, Seloken, Lokelma, Roxadustat, Andexxa, Wainua, Symbicort, Fasenra, Pulmicort, Breztri/Trixeo, Saphnelo, Tezspire, Airsupra, Ultomiris, Soliris, Strensiq, Koselugo, Kanuma, Atacand, Plendil, Modip, Splendil, Munobal, Flodil, Komboglyze, Qtern, Byetta, XIGDUO, Accolate, Accoleit, Vanticon, Beyfortus, Synagis, FluMist, tixagevimab and cilgavimab, and sipavibart. It also provides Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Bricanyl Turbuhaler, Rhinocort, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Breztri Aerosphere, Duaklir Genuair, Kavigale, Evusheld, Fluenz/FluMist, and Voydeya. The company offers its products for ocology, cardiovascular, renal and metabolism, respiratory & immunology, vaccines and immune, and therapies rare diseases. It serves primary and specialty care physicians through distributors and local representative offices in the United Kingdom, the United States, Europe, and Asia. It has a strategic agreement with Tempus to develop the largest multimodal foundation model in oncology. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Fundamentals for AstraZeneca PLC ADR

Market Capitalization
$215,692,034,048
EBITDA
$17,567,000,576
Dividends per Share
$3.10
P/E Ratio
30.92
Forward P/E Ratio
15.77
Earnings per Share
$2.25
Earnings per Share Estimate Next Year
Profit Margin
13.01%
Shares Outstanding
3,100,359,936
Percent Owned by Insiders
0.00%
Percent Owned by Institutions
17.49%
52-Week High
52-Week Low

Technical Indicators for AstraZeneca PLC ADR

50-Day Moving Average
200-Day Moving Average
RSI
49.13
1.9

Analyst Ratings for AstraZeneca PLC ADR

Strong Buy
6
Buy
4
Hold
1
Sell
0
Strong Sell
0

News About AstraZeneca PLC ADR

Apr 25, 2025, 4:49 AM EST
For Immediate Release See more.
Apr 25, 2025, 1:00 AM EST
Earnings season is now in full swing, with a number of key companies due to report in the coming week, including four of the Magnificent 7 tech giants in focus. See more.
Apr 24, 2025, 5:00 PM EST
LAKE FOREST, Calif., April 24, 2025--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced changes to its Board of Directors. See more.
Apr 24, 2025, 3:00 PM EST
Tempus AI TEM has skyrocketed 21% in the last three days, fueled by news of a $200 million partnership with AstraZeneca AZN and Pathos AI. See more.